{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05519072",
            "orgStudyIdInfo": {
                "id": "1889711-1"
            },
            "organization": {
                "fullName": "Atlantic Health System",
                "class": "OTHER"
            },
            "briefTitle": "Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA",
            "officialTitle": "Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA Treatment of Overactive Bladder: a Randomized Controlled Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "use-of-prophylactic-antibiotics-prior-to-onabotulinumtoxina"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-16",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-16",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-25",
            "studyFirstSubmitQcDate": "2022-08-25",
            "studyFirstPostDateStruct": {
                "date": "2022-08-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Carolyn Botros",
                "investigatorTitle": "Associate Program Director FPMRS Fellowship, Principal Investigator",
                "investigatorAffiliation": "Atlantic Health System"
            },
            "leadSponsor": {
                "name": "Atlantic Health System",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Columbia University",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study aims to show that lack of antibiotic prophylaxis to those undergoing bladder Botox injections is not significantly inferior to administering prophylaxis. By proving this, the investigators aim to decrease antibiotic use in this setting to combat the growing issue of antibiotic resistance.\n\nParticipants will be randomized to antibiotic or no treatment arm. Those randomized to the treatment arm will receive oral antibiotics for 2 days pre-treatment, on the treatment day, and 2 days post-treatment. Participants will return for a follow up appointment approximately 2 weeks after treatment to assess for urinary tract infection (UTI) symptoms. They will be called again at 6 weeks for follow up.",
            "detailedDescription": "Single-centered, randomized-controlled trial. Participants will be randomized to antibiotic or no treatment arm. All subjects will obtain a urine culture approximately 14 days before the procedure. Those randomized to the treatment arm will receive oral antibiotics at the discretion of physician in accordance to patient's allergies. Antibiotics will be administered for 2 days pre-treatment, on the treatment day, and 2 days post-treatment.\n\nTechnique and dose of Botox injection will be at the discretion of the operating physician. Participants will return for a follow up appointment approximately 2 weeks after treatment as is standard, to check a post void residual. They will be called again at 6 weeks for follow up. The investigators will assess for urinary tract infection symptoms, voiding dysfunction, and other adverse events potentially related to the prophylactic antibiotics. Urine cultures will be collected, when possible, to confirm infection for patients developing symptoms.\n\nFor the sample size calculation, the investigators assume an alpha (\u03b1) value of 0.05 and a power of 80%. The UTI rate after the bladder Botox procedure is 20% (Chapple et al) and the investigators have chosen a \u03b4 of 20%. This was chosen because it was the largest amount the investigators found acceptable to presume the no antibiotic group non-inferior. Using these calculations, 64 persons are needed per study arm. With a 10% drop out rate, a total sample size would equal 140 patients total, with 70 per arm.\n\nIf participants are found to meet inclusion criteria, they will be contacted by the study team to assess for desired participation in the study. If the patient is agreeable to participate, a phone or in person consent will be obtained and the patient will be randomized. All participants, regardless of study arm, will have a urine culture collected preoperatively, approximately 14 days before procedure. If found to have a UTI, the participants will be treated accordingly. Those in the no antibiotic treatment arm will not receive any antibiotic prophylaxis and will undergo Botox injection. Those in the treatment arm will receive oral antibiotics prescribed at discretion of physician in accordance to participant's allergies.\n\nThe primary concern is the development of adverse side effects to antibiotics. Subjects will be monitored throughout the study for these potential adverse events by screening for symptoms. If an event occurs, the PI will be notified immediately. It will also be reported to the Institutional Review Board (IRB) and to all members of the research team."
        },
        "conditionsModule": {
            "conditions": [
                "Antibiotic Prophylaxis"
            ],
            "keywords": [
                "Antibiotics",
                "Botox",
                "OnabotulinumtoxinA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Antibiotic arm",
                    "type": "EXPERIMENTAL",
                    "description": "Antibiotics will be administered for 2 days pre-treatment, on the treatment day, and 2 days post-treatment.",
                    "interventionNames": [
                        "Drug: Nitrofurantoin"
                    ]
                },
                {
                    "label": "No treatment arm",
                    "type": "NO_INTERVENTION",
                    "description": "No antibiotics administered."
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nitrofurantoin",
                    "description": "For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.",
                    "armGroupLabels": [
                        "Antibiotic arm"
                    ],
                    "otherNames": [
                        "Trimethoprim/Sulfamethoxazole",
                        "Trimethoprim",
                        "Cefalexin",
                        "Ciprofloxacin",
                        "Augmentin",
                        "Fosfomycin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Urinary tract infections",
                    "description": "Number of participants with urinary tract infections",
                    "timeFrame": "2 weeks post-procedure"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Urinary tract infections",
                    "description": "Number of participants with urinary tract infections",
                    "timeFrame": "6 weeks post-procedure"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Urinary retention and adverse reactions",
                    "description": "Number of participants with reactions to antibiotics and urinary retention",
                    "timeFrame": "6 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Female\n* Age \u2265 18\n* Patient undergoing bladder Botox treatment\n\nExclusion Criteria:\n\n* Pregnant and/or breastfeeding\n* Contraindication to injection of Botox - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, symptomatic urinary retention or post void residual (PVR) \\> 200 mL, unwillingness or inability to initiate clean intermittent catheterization (CIC) post-treatment if required.\n* Contraindication to oral antibiotics - hypersensitivity or allergy\n* Inability to take medication by mouth",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Anastasiya Holubyeva, MD",
                    "role": "CONTACT",
                    "phone": "9739717267",
                    "email": "anastasiya.holubyeva@atlantichealth.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Carolyn Botros, DO",
                    "affiliation": "Atlantic Health System",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Atlantic Health",
                    "status": "RECRUITING",
                    "city": "Morristown",
                    "state": "New Jersey",
                    "zip": "07962-1905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lyudmila Babaev",
                            "role": "CONTACT",
                            "phone": "862-246-4973",
                            "email": "lyudmila.babaev@atlantichealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.79677,
                        "lon": -74.48154
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "27038769",
                    "type": "BACKGROUND",
                    "citation": "Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C; 191622-096 Investigators. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep;196(3):791-800. doi: 10.1016/j.juro.2016.03.146. Epub 2016 Mar 30."
                },
                {
                    "pmid": "26347077",
                    "type": "BACKGROUND",
                    "citation": "Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L. Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol. 2015 Oct;47(10):1619-27. doi: 10.1007/s11255-015-1100-3. Epub 2015 Sep 7."
                },
                {
                    "pmid": "24754838",
                    "type": "BACKGROUND",
                    "citation": "Sievert KD, Chapple C, Herschorn S, Joshi M, Zhou J, Nardo C, Nitti VW. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014 Oct;68(10):1246-56. doi: 10.1111/ijcp.12443. Epub 2014 Apr 22."
                },
                {
                    "pmid": "26999201",
                    "type": "BACKGROUND",
                    "citation": "Kuo YC, Kuo HC. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction? Toxins (Basel). 2016 Mar 16;8(3):75. doi: 10.3390/toxins8030075."
                },
                {
                    "pmid": "30074062",
                    "type": "BACKGROUND",
                    "citation": "Houman J, Moradzadeh A, Patel DN, Asanad K, Anger JT, Eilber KS. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. Int Urogynecol J. 2019 May;30(5):701-704. doi: 10.1007/s00192-018-3721-4. Epub 2018 Aug 3."
                },
                {
                    "pmid": "31288031",
                    "type": "BACKGROUND",
                    "citation": "Wencewicz TA. Crossroads of Antibiotic Resistance and Biosynthesis. J Mol Biol. 2019 Aug 23;431(18):3370-3399. doi: 10.1016/j.jmb.2019.06.033. Epub 2019 Jul 6."
                },
                {
                    "pmid": "33400359",
                    "type": "BACKGROUND",
                    "citation": "Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence-Implications for human health and treatment perspectives. EMBO Rep. 2020 Dec 3;21(12):e51034. doi: 10.15252/embr.202051034. Epub 2020 Dec 8."
                },
                {
                    "pmid": "33594517",
                    "type": "BACKGROUND",
                    "citation": "Eckhardt SE, Takashima Y, Handler SJ, Tenggardjaja C, Yazdany T. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. Int Urogynecol J. 2022 Mar;33(3):703-709. doi: 10.1007/s00192-021-04691-4. Epub 2021 Feb 16."
                },
                {
                    "pmid": "31441676",
                    "type": "BACKGROUND",
                    "citation": "Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol. 2020 Feb;203(2):351-356. doi: 10.1097/JU.0000000000000509. Epub 2019 Aug 23."
                },
                {
                    "pmid": "27177011",
                    "type": "BACKGROUND",
                    "citation": "Khan MH, Baldo O, Koenig P, Shaikh N. Use of prophylactic antibiotics for intra-vesicle Botox(R) injection. Neurourol Urodyn. 2017 Mar;36(3):828. doi: 10.1002/nau.23034. Epub 2016 May 13."
                },
                {
                    "pmid": "23608668",
                    "type": "BACKGROUND",
                    "citation": "Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M27167",
                    "name": "Urinary Bladder, Overactive",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002939",
                    "term": "Ciprofloxacin"
                },
                {
                    "id": "D000019980",
                    "term": "Amoxicillin-Potassium Clavulanate Combination"
                },
                {
                    "id": "D000002506",
                    "term": "Cephalexin"
                },
                {
                    "id": "D000005578",
                    "term": "Fosfomycin"
                },
                {
                    "id": "D000009582",
                    "term": "Nitrofurantoin"
                },
                {
                    "id": "D000014295",
                    "term": "Trimethoprim"
                },
                {
                    "id": "D000013420",
                    "term": "Sulfamethoxazole"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065609",
                    "term": "Cytochrome P-450 CYP1A2 Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000000892",
                    "term": "Anti-Infective Agents, Urinary"
                },
                {
                    "id": "D000000962",
                    "term": "Antimalarials"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000005493",
                    "term": "Folic Acid Antagonists"
                },
                {
                    "id": "D000018726",
                    "term": "Anti-Dyskinesia Agents"
                },
                {
                    "id": "D000065687",
                    "term": "Cytochrome P-450 CYP2C8 Inhibitors"
                },
                {
                    "id": "D000065093",
                    "term": "beta-Lactamase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M8700",
                    "name": "Fosfomycin",
                    "asFound": "Adjunctive Therapy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12519",
                    "name": "Nitrofurantoin",
                    "asFound": "Endotoxin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21257",
                    "name": "Botulinum Toxins, Type A",
                    "relevance": "LOW"
                },
                {
                    "id": "M250193",
                    "name": "abobotulinumtoxinA",
                    "relevance": "LOW"
                },
                {
                    "id": "M17047",
                    "name": "Trimethoprim",
                    "asFound": "Decision aid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16206",
                    "name": "Sulfamethoxazole",
                    "asFound": "Weaning",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21845",
                    "name": "Amoxicillin-Potassium Clavulanate Combination",
                    "asFound": "Cava",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6176",
                    "name": "Ciprofloxacin",
                    "asFound": "Loop",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5755",
                    "name": "Cephalexin",
                    "asFound": "Ovarian epithelial cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3995",
                    "name": "Amoxicillin",
                    "relevance": "LOW"
                },
                {
                    "id": "M6204",
                    "name": "Clavulanic Acids",
                    "relevance": "LOW"
                },
                {
                    "id": "M21710",
                    "name": "Clavulanic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4280",
                    "name": "Antimalarials",
                    "relevance": "LOW"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M8619",
                    "name": "Folic Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30450",
                    "name": "beta-Lactamase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}